Back to the main directory
EarningsReview / Equity
- Constructive commentary from SCHOTT Pharma and West Pharma by BNP Paribas Exane
- Kalmar - Demand starting to improve by Danske Bank Equity Research
- Revenio - Good things come to those who are patient by Danske Bank Equity Research
- Towards faster growth and more cash returns by BNP Paribas Exane
- FY 2024 Results: 4% EBIT beat, 4Q Moncler DTC at 9% by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Stevie Wonder by BNP Paribas Exane
- SAP Business Unleashed: product event feedback by BNP Paribas Exane
- FY24 results and 15 questions for management by BNP Paribas Exane
- Unconvincing by BNP Paribas Exane
- First look F2Q25: Top-line/margins ok but some billings noise by BNP Paribas Exane
- Polymer uncertainty outweighs destocking optimism by BNP Paribas Exane
- KID (Buy, TP: NOK175.00) - Q4 margins a tad soft by DnB Markets
- Alimak (Hold, TP: SEK140.00) - Strong end to the year by DnB Markets
- ALK-Abello (Buy, TP: DKK190.00) - Expecting strong year end by DnB Markets
- Avance Gas (Sell, TP: NOK76.00) - Wind-down in progress by DnB Markets
- Lime Technologies (Hold, TP: SEK375.00) - Cautiously optimistic comments by DnB Markets
- Crayon (Hold, TP: NOK112.00) - Seeing more balanced risk/reward by DnB Markets
- Paradox Interactive (Buy, TP: SEK260.00) - A return to form by DnB Markets
- 2020 Bulkers (Hold, TP: NOK125.00) - Potential on HOLD by market lull by DnB Markets
- Elkem (Hold, TP: NOK30.00) - Preparing to unlock values by DnB Markets
- Aker BP (Buy, TP: NOK280.00) - Set for operating tailwinds in 2025 by DnB Markets
- Genmab (Buy, TP: DKK2500.00) - Next up: HexaBody-CD38 decision by DnB Markets
- SFL Corporation Ltd (Hold, TP: USD10.80) - Scales balanced on risk/reward by DnB Markets
- Odfjell Technology (Buy, TP: NOK70.00) - Earnings growth conviction needed by DnB Markets
- Clearer skies ahead by BNP Paribas Exane
- Airports of Thailand (AOT TB) by HSBC
- FY24: small earnings beat and return to dividend growth by BNP Paribas Exane
- Looking ahead with confidence by BNP Paribas Exane
- FY24 results and 15 questions for management by BNP Paribas Exane
- Solid Q4 but cash flow concerns remain by BNP Paribas Exane
- Post-view: Mid-20% FY25 Revenue growth still achievable by BNP Paribas Exane
- Q325 trading and 15 questions for management by BNP Paribas Exane
- Cognac shipments - Jan'25: material decline by BNP Paribas Exane
- FY24 results and 15 questions for management by BNP Paribas Exane
- Q4 in line, Super Bowl sets records by BNP Paribas Exane
- Q4 largely in line; 2025 EPS meets Street expectations by BNP Paribas Exane
- Elmera Group (Sell, TP: NOK24.00) - Q4 above, uncertainty remains by DnB Markets
- Hafnia (Buy, TP: NOK84.00) - Shareholder-friendly powerhouse by DnB Markets
- Gentian Diagnostics (Buy, TP: NOK67.00) - Solid end to the year by DnB Markets
- Catella (Buy, TP: SEK35.00) - Building back better by DnB Markets
- NCAB (Buy, TP: SEK70.00) - Disappointing Q4, but future positive by DnB Markets
- Instalco (Buy, TP: SEK48.00) - Soft as expected, but signs of upturn by DnB Markets
- Arctic Fish (Buy, TP: NOK80.00) - Neutral Q4 report by DnB Markets
- Mowi (Hold, TP: NOK245.00) - Supply growth ahead by DnB Markets
- Solstad Offshore (Buy, TP: NOK60.00) - Set to enter a dividend phase by DnB Markets
- BlueNord (Hold, TP: NOK680.00) - The dividend tap has opened by DnB Markets
- Elkem (Buy, TP: NOK30.00) - Preparing to unlock values by DnB Markets
- SpareBank 1 Østlandet (Hold, TP: NOK158.00) - Solid post-merger quarter by DnB Markets
- B2Impact (Buy, TP: NOK12.00) - Supportive distribution outlook by DnB Markets